Efficacy of afzlibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis

Arquivos Brasileiros de Oftalmologia

Volumn 79, Issue 6, 2016, Pages 384-389

  Gokce, Gokcen ^a   Durukan, Ali Hakan ^b   Koylu, Mehmet Talay ^c   Kucukevcilioglu, Murat ^b  

^a Kayseri Military Hospital   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c Tatvan Military Hospital   (Turkey)

Author keywords

Angiogenesis inhibitors; Macular degeneration; Ranibizumab; Tachyphylaxis; Vascular endothelial growth factor A

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; RANIBIZUMAB; VASCULOTROPIN RECEPTOR;

AGED; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; SECRETION (PROCESS); SUBRETINAL FLUID; TACHYPHYLAXIS; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DRUG RESISTANCE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; SUBRETINAL FLUID; TACHYPHYLAXIS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 85009477632     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.5935/0004-2749.20160109     Document Type: Article

References (27)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31. Comment in: N Engl J Med. 2006;355(14):1409-12; N Engl J Med. 2007;356(7):748-9. N Engl J Med. 2007;356(7):747-8/author reply 740-50. N Engl J Med. 2006;355(14):1493-5.
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009; 116(1):57-65 e5. Comment in: Ophthalmology. 2009;116(8):1593.
3. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605-12.
4. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-908.Comment in: N Engl J Med. 2011;364(20):1966-7; N Engl J Med.2011;365(23):2238; N Engl J Med. 2011;365(23):2237; author reply 2237. JAMA. 2014;311(15):1491-2; Clin Experiment Ophthalmol. 2011;39(7):718-20.
5. Comparison of Age-related Macular Degeneration Treatments Trials(CATT) Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98. Comment in: J Comp Eff Res. 2012;1(6):485-8; JAMA Opthalmol. 2015;133(3):363-4. JAMA Opthalmol. 2015;133(6):726.
6. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1-2. Comment in: Br J Ophthalmol. 2012;96(1):21-3. Br J Ophthalmol. 2012;96(1):14-20.
7. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013; 120(5):1046-56.
8. Wykoff CC, Brown DM, Croft DE, Wong TP. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013;120(9):1945-6 e1.
9. Wykoff CC, Brown DM, Chen E, Major JC, Croft DE, Mariani A, Wong TP; SAVE Study Group. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013;44(2):121-6. Ophthalmic Surg Lasers Imaging Retina. 2013;44(2):109.
10. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-85.
11. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156(1):15-22 e1.
12. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-48. Erratum in: Ophthalmology. 2013; 120(1):209-10.
13. Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, Nishijo K, Sowade O, Komori T, Schmidt-Erfurth U, Simader C, Chong V; VIEW 2 Investigators. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99(1):92-7.
14. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
15. Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(3):426-36 e2. Comment in: Am J Ophthalmol. 2015; 159(5):996-7.
16. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):188-92.
17. Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. BioMed Res Int. 2014;2014:273754.
18. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156(1): 23-8 e2.
19. Singh RP, Srivastava S, Ehlers JP, Bedi R, Schachat AP, Kaiser PK. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol. 2014; 98 Suppl 1:i22-7.
20. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35 e2.
21. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96(1):14-20. Comment in: Br J Ophthalmol. 2012;96(1):1-2.
22. Egho MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21-3.Comment in: Br J Ophthalmol. 2012;96(1):1-2.
23. Holladay JT. Visual acuity measurements. J Cataract Refract Surg. 2004;30(2):287-90.
24. Ijiri S, Sugiyama K. Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy. Graefe's Arch Clin Exp Ophthalmol. 2015;253(3):351-7.
25. Miura M, Iwasaki T, Goto H. Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol. 2013;7:1591-5.
26. Hariri A, Diniz B, Fou LV, Lam LA, Nittala MG, Sadda SR. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. Ophthalmic Surg Lasers Imaging Retina. 2015;46(2):195-200.
27. Broadhead GK, Hong T, Zhu M, Li H, Schlub TE, Wijeyakumar W, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina. 2015;35(5): 975-81.